SARMs in Breast Cancer

Because the SARM we use in the breast cancer program targets the androgen receptor, but is non-steroidal, it cannot be converted to other hormones by common enzymes, and therefore does not cause effects in other hormone systems in the same way that other androgens and steroids do.

Our clinical (and preclinical) data shows activity in two types of breast cancer patients:

  • women whose tumors are estrogen and androgen receptor positive
  • women with androgen receptor positive but triple negative (estrogen, progesterone and HER2 negative) breast cancer